Eli Lilly (NYSE:LLY) debuted its best-selling diabetes therapy, Mounjaro, in an easy-to-use injector format in India on Wednesday, escalating a rivalry with Novo Nordisk (NVO) in the world’s most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback